Biologic Therapy in Head and Neck Cancer: A Road with Hurdles

Table 1

Planned or ongoing trials with cetuximab in SCCHN.

Trial phase	Disease setting	Associated treatment	Comparator
Phase III	LA resectable	TP before surgery	Surgery + RT
	LA	RT (after TPF ICT)	RT + P
	LA	RT after TPF	RT + P or CRT
	LA HPV + OPH	RT	P
	LA resected	RT	none
Randomized phase II	LA	RT	P
	LA	TPF or paclitaxel + carbo
	LA	Adjuvant after CRT + cetuximab	none
	R/M	Temsirolimus
	LA ICT	TPF or paclitaxel/P
Single arm phase II	LA	RT + (P or carbo) + NABP
	LA	(Accelerated) RT
	LA ICT	TPF
	LA ICT	TP
	LA ICT	Paclitaxel/P → RT
	LA after TPF ICT	RT
	LA resected	CRT
	LA after carbo/paclitaxel ICT	RT + P
	Adjuvant after CRT	None
	Local recurrence	BNCT
	Local recurrence	RT
	Local recurrence	RT + P
	Local recurrence	Radiosurgery
	Reirradiation	RT
	R/M	carbo/P + pemetrexed
	R/M	TP
	R/M 2nd	carbo + vinorelbine

LA: locoregionally advanced; R/M: recurrent/metastatic; RT: radiotherapy; P: cisplatin.
T: docetaxel; F: 5-fluorouracil; carbo: carboplatin; ICT: induction chemotherapy.
2nd: second line; NABP: nanoparticle albumin-bound paclitaxel.
BNCT: boron neutron capture therapy; CRT: concurrent chemoradiation; OPC: oropharyngeal cancer.